Core Viewpoint - The company, Zhifei Biological, has received approval from the National Medical Products Administration for clinical trials of its CA111 injection in overweight or obese adult patients [1] Group 1 - Zhifei Biological announced that its subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has developed the CA111 injection [1] - The approval notification for the clinical trial is identified by the numbers 2025LP02405 and 2025LP02406 [1] - The clinical trials will focus on adult patients who are overweight or obese [1]

Core Viewpoint - The announcement by Zhifei Biological indicates that its subsidiary, Chonqing Chen'an Biopharmaceutical Co., Ltd., has received approval for clinical trials of CA111 injection, a dual agonist for GIP and GLP-1 receptors, aimed at treating overweight or obese adults [1][2]. Group 1: Product Development - CA111 injection is designed to stimulate insulin secretion and protect pancreatic beta cells, thereby controlling blood sugar and weight through the synergistic effects of GIP and GLP-1 [1][2]. - The dual receptor agonist mechanism of CA111 is expected to reduce side effects compared to single-target drugs, with no other similar products approved in the domestic market as of the announcement date [2]. Group 2: Market Potential - The innovative drug CA111 is classified as a Class 1 chemical drug, with Zhifei holding effective patents for its molecular structure and uses, indicating a broad market potential in diabetes and weight management [2]. - The company aims to enhance its integrated "prevention & treatment" strategy and leverage the collaborative value of its pipeline through the successful development of CA111 [2]. Group 3: Strategic Expansion - In March, Zhifei acquired a 51% stake in Chen'an Biopharmaceutical, expanding its research and development focus from vaccines to metabolic diseases, thus entering the therapeutic biopharmaceutical sector [3]. - Chen'an Biopharmaceutical is actively developing a pipeline focused on diabetes and obesity, with several products in various stages of clinical trials and partnerships with overseas entities [3]. Group 4: Financial Outlook - The global sales of semaglutide, a key product in the metabolic disease treatment market, reached approximately $16.683 billion, with $550 million in sales in China during the first half of 2025, highlighting the lucrative market potential for Zhifei's future products [3].

Core Viewpoint - Zhifei Biological (300122) announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Company Developments - The CA111 injection developed by Chen'an Biological is designed to reduce side effects compared to similar single-target drugs due to its dual agonist synergistic effect [1]

Core Viewpoint - Zhifei Biological announced that its subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1 - The CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor [1] - Compared to single-target similar drugs, the dual agonist can effectively reduce the side effects of administration due to synergistic and complementary effects [1]

Core Viewpoint - The company Zhifei Biological (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its innovative drug CA111 injection, targeting overweight or obese adults, indicating a significant advancement in its product pipeline [1] Group 1 - The CA111 injection is developed by the company's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., and is classified as a Class 1 chemical drug [1] - The company holds effective invention patents for the molecular structure and use of CA111, highlighting its proprietary technology in the diabetes and weight loss treatment market [1] - The development of CA111 injection reflects the company's focus on innovative technologies and enhancing research capabilities, which is expected to strengthen its integrated "prevention & treatment" layout [1] Group 2 - Successful progress of the CA111 project could enhance the company's pipeline synergy value and promote sustainable development [1]

Core Viewpoint - Hefei High-tech Zone aims to become a significant hub for the synthetic biology industry, focusing on innovation in four key areas: biomaterials, biomedicine, bio-agriculture, and bio-foods [2][3]. Group 1: Development Plan - The "Implementation Plan for Synthetic Biology Industry Development" was officially released, emphasizing the importance of resource aggregation and promoting high-end, green development in the industry [2]. - A special fund of no less than 3 billion yuan will be established to support the industrialization of major achievements, alongside collaboration with financial institutions to innovate financial products [2]. Group 2: Industry Foundation - The synthetic biology industry in Hefei High-tech Zone has established a solid foundation, featuring a dual-driven model of "enterprises + platforms" [2]. - Over 30 core enterprises have been cultivated, including Anke Bio, Zhifei Longkema, and Zhaoke Pharmaceutical, covering critical areas such as antibody drugs and new vaccines [2]. Group 3: Future Goals - By 2027, the plan aims to nurture more than 10 enterprises with a production value exceeding 100 million yuan, at least 3 enterprises with over 500 million yuan, and 1 enterprise surpassing 1 billion yuan [3]. - The goal is to gather no less than 50 enterprises in the synthetic biology industry chain, with a total production value exceeding 10 billion yuan [3].

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Product Development - CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a gastrointestinal regulatory peptide consisting of 42 amino acids, which stimulates insulin secretion from pancreatic beta cells and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a peptide of 37 amino acids that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist mechanism of GIP and GLP-1 can achieve synergistic effects for better glucose-lowering and weight loss outcomes [1]

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Product Development - CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist mechanism of GIP and GLP-1 can achieve synergistic effects for better glucose-lowering and weight loss outcomes [1]

Core Viewpoint - Zhifei Biological announced that its subsidiary, Chen'an Biological, received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults, indicating a significant step in its drug development process [1] Group 1: Company Developments - The CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, suggesting a broad market potential for the product [1] - The approval allows the company to conduct clinical trials, which is a critical phase in the drug development lifecycle [1] Group 2: Industry Context - Drug development is characterized by high investment, long cycles, and significant risks, highlighting the challenges that the company may face in bringing CA111 to market [1] - There is uncertainty regarding the progress and results of subsequent clinical trials, as well as the timeline for product commercialization [1]

重庆智飞生物制品股份有限公司 关于 CA111 注射液获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300122 证券简称：智飞生物 公告编号：2025-52 CA111 注射液系宸安生物开发的创新药，根据药品注册分类属于化学药品 1 类。宸安生物拥有 CA111 分子结构和用途的有效发明专利，在糖尿病和减重治 疗领域，产品市场前景广阔。 公司开拓双激动剂创新药 CA111 注射液的研发，是聚焦创新技术、增强科 研攻关的结果。若本项目进展顺利，将夯实丰富公司"预防&治疗"一体化布局， 凸显公司管线协同价值，促进公司实现可持续发展。 三、风险提示 1、药品研制是非常复杂严谨的科学活动，具有投入大，周期长，风险高的 特点，产品的研发和行政审批主要有以下几个阶段：临床前研究；申请临床试验； 开展临床试验；申请生产文号；上市销售。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日获悉，由控股子 公司重庆宸安生物制药有限公司（以下简称"宸安生物"）研发的 CA111 注射液 获得国家药品监督管理局药物临床试验批准通知书（通 ...